Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05348889
What this trial is testing

First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

Who this might be right for
Non-Hodgkin's Lymphoma (disorder)Acute Lymphoid Leukemia, Disease (disorder)
Chimagen Biosciences, Ltd 7
Testing effectiveness (Phase 2)Ended earlyNCT02391545
What this trial is testing

Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Who this might be right for
CD20+ Follicular Lymphoma
SecuraBio 55
Testing effectiveness (Phase 2)Study completedNCT00280878
What this trial is testing

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma (CD20+)
Bayside Health 12
Early research (Phase 1)Looking for participantsNCT06703892
What this trial is testing

Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Who this might be right for
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma RefractoryFollicular Lymphoma ( FL)+3 more
GenomeFrontier Therapeutics TW Co., Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT06996132
What this trial is testing

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 25
Testing effectiveness (Phase 2)Ended earlyNCT05360238
What this trial is testing

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Who this might be right for
Follicular B-cell Non-Hodgkin's LymphomaMantle Cell Lymphoma RecurrentMantle Cell Lymphoma Refractory+5 more
Mustang Bio 20
Early research (Phase 1)Looking for participantsNCT06249438
What this trial is testing

C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Who this might be right for
Systemic Lupus Erythematosus (SLE)Immune-mediated Necrotizing Myopathy (IMNM)Neuromyelitis Optica Spectrum Disorders (NMOSD)+3 more
RenJi Hospital 30
Early research (Phase 1)Temporarily pausedNCT04746131
What this trial is testing

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 90
Testing effectiveness (Phase 2)UnknownNCT01279902
What this trial is testing

Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Asan Medical Center 32
Large-scale testing (Phase 3)Active Not RecruitingNCT05100862
What this trial is testing

Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Who this might be right for
Relapsed/Refractory Follicular LymphomaMarginal Zone Lymphoma
BeOne Medicines 799
Early research (Phase 1)UnknownNCT06364852
What this trial is testing

An Evaluation of LY007 Cell Injection for r/r B-NHL

Who this might be right for
B-NHL
Ruijin Hospital 18
Testing effectiveness (Phase 2)UnknownNCT02737085
What this trial is testing

The Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Southwest Hospital, China 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07569965
What this trial is testing

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

Who this might be right for
Mantle Cell Lymphoma (MCL)
Miltenyi Biomedicine GmbH 52
Early research (Phase 1)Active Not RecruitingNCT05206357
What this trial is testing

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Who this might be right for
Non-hodgkin Lymphoma
Genmab 17
Large-scale testing (Phase 3)Active Not RecruitingNCT06230224
What this trial is testing

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals 216
Early research (Phase 1)Ended earlyNCT05987605
What this trial is testing

Phase I/II Clinical Study of 1A46 Drug Substance

Who this might be right for
Advanced Malignancies
BioRay Pharmaceutical Co., Ltd. 4
Testing effectiveness (Phase 2)Ended earlyNCT02151903
What this trial is testing

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

Who this might be right for
B-cell Non-Hodgkin Lymphoma
Alopexx Oncology, LLC 5
Early research (Phase 1)Study completedNCT00825149
What this trial is testing

Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 137
Testing effectiveness (Phase 2)UnknownNCT04304040
What this trial is testing

MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Beijing InnoCare Pharma Tech Co., Ltd. 43
Testing effectiveness (Phase 2)Study completedNCT03485118
What this trial is testing

RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Zhejiang Hisun Pharmaceutical Co. Ltd. 137
Next Page